{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:14:18Z","timestamp":1792545258293,"version":"4.5.0"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001543","name":"Neurological Foundation of New Zealand","doi-asserted-by":"publisher","award":["2003\/CHF"],"award-info":[{"award-number":["2003\/CHF"]}],"id":[{"id":"10.13039\/501100001543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially disabling complication of the neurotoxic chemotherapies; however, its occurrence is often unpredictable. We aimed to determine whether serum levels of neurofilament light chain (sNfL) could predict the onset and severity of CIPN, and whether sNfL levels were associated with other clinical factors in people with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients (&gt;18 years) prescribed at least four cycles of oxaliplatin, cisplatin, docetaxel or paclitaxel were clinically assessed and had blood taken for sNfL analysis at baseline and prior to each cycle. Peak sNfL was compared with clinical characteristics and Total Neuropathy Score-Clinical version (TNSc), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, V.4.03) and CIPN-Rasch-built Overall Disability Scale (CIPN-RODS). Individual patient trends in sNfL and TNSc were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>42 patients completed the study, with 36 receiving platinum agents and 6 receiving taxanes. Peak sNfL was higher with taxanes than with platinum agents (129.9 vs 31.0\u2009pg\/mL; p&lt;0.0001). Higher peak sNfL was not associated with final TNSc, CTCAE or CIPN-RODS in patients receiving platinum agents. Using age-adjusted NfL z-scores, peak sNfL was associated with CIPN-RODS (rs=\u22120.45; p=0.012) and was higher in patients with a final CTCAE Grade of 2 compared with Grades 0\u20131 (p=0.015) but was not associated with final TNSc (rs=+0.37, p=0.050). In patients receiving platinum agents, higher peak sNfL was associated with death within 6 months of study entry (p=0.020). sNfL rose in conjunction with the increase in TNSc but did not precede clinical symptoms\/signs of neuropathy in most patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taxanes cause greater and sharper sNfL rises than platinum agents. Age-adjusted sNfL associates with neuropathy severity in platinum-treated patients; however, in most patients it is unable to detect early axonal damage before this is detectable with clinical examination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001312","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:15:20Z","timestamp":1767687320000},"page":"e001312","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective assessment of serum neurofilament light chain in platinum-induced and taxane-induced peripheral neuropathy"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-8611","authenticated-orcid":false,"given":"Duncan","family":"Smyth","sequence":"first","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"Queen Square Centre for Neuromuscular Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Y S","family":"Keh","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"Queen Square Centre for Neuromuscular Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Keddie","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"Queen Square Centre for Neuromuscular Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chou","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"NHS Neuroimmunology and CSF Laboratory, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hart","sequence":"additional","affiliation":[{"name":"NHS Neuroimmunology and CSF Laboratory, UCL Queen Square Institute of Neurology, London, UK"},{"name":"Neuroinflammation, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Chapman","sequence":"additional","affiliation":[{"name":"NHS Neuroimmunology and CSF Laboratory, UCL Queen Square Institute of Neurology, London, UK"},{"name":"Neuroinflammation, UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D","family":"Forster","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, London, UK"},{"name":"Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Carr","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"Queen Square Centre for Neuromuscular Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases, UCL, London, UK"},{"name":"Queen Square Centre for Neuromuscular Diseases, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026051208151364000_8.1.e001312.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951"},{"key":"2026051208151364000_8.1.e001312.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"2026051208151364000_8.1.e001312.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102831"},{"key":"2026051208151364000_8.1.e001312.4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7286"},{"key":"2026051208151364000_8.1.e001312.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.02.003"},{"key":"2026051208151364000_8.1.e001312.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2026051208151364000_8.1.e001312.7","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01136-0"},{"key":"2026051208151364000_8.1.e001312.8","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1038\/s41598-020-64511-5","article-title":"Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"2026051208151364000_8.1.e001312.9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jns.12493","article-title":"Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients","volume":"27","author":"Karteri","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"2026051208151364000_8.1.e001312.10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942960","article-title":"Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"2026051208151364000_8.1.e001312.11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154395","article-title":"Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy","volume":"7","author":"Huehnchen","year":"2022","journal-title":"JCI Insight"},{"key":"2026051208151364000_8.1.e001312.12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","article-title":"Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer","volume":"164","author":"Mortensen","year":"2023","journal-title":"Pain"},{"key":"2026051208151364000_8.1.e001312.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174216","article-title":"Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy","volume":"15","author":"Cavaletti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026051208151364000_8.1.e001312.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18716-5","article-title":"Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin","volume":"12","author":"Burgess","year":"2022","journal-title":"Sci Rep"},{"key":"2026051208151364000_8.1.e001312.15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","article-title":"Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity","volume":"270","author":"Velasco","year":"2023","journal-title":"J Neurol"},{"key":"2026051208151364000_8.1.e001312.16","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16369","article-title":"Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug","volume":"31","author":"Velasco","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026051208151364000_8.1.e001312.17","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","article-title":"Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment","volume":"270","author":"Cebulla","year":"2023","journal-title":"J Neurol"},{"key":"2026051208151364000_8.1.e001312.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2007.00141.x"},{"key":"2026051208151364000_8.1.e001312.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.004"},{"key":"2026051208151364000_8.1.e001312.20","unstructured":"National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf [Accessed 15 Dec 2025]."},{"key":"2026051208151364000_8.1.e001312.21","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.11.1281"},{"key":"2026051208151364000_8.1.e001312.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.056"},{"key":"2026051208151364000_8.1.e001312.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"2026051208151364000_8.1.e001312.24","unstructured":"Quanterix . Discover the Simoa(R) LDT NfL test for highly sensitive detection of neurofilament light chain. Available: https:\/\/www.quanterix.com\/simoa-assay-kits\/nfl-ldt [Accessed 20 Oct 2025]."},{"key":"2026051208151364000_8.1.e001312.25","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-025-04773-w","article-title":"Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy","volume":"95","author":"Gehr","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026051208151364000_8.1.e001312.26","first-page":"S26","article-title":"Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24 Suppl 2","author":"Staff","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2026051208151364000_8.1.e001312.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113121"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:15:22Z","timestamp":1778598922000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001312"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001312","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}